An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Xtandi

Chemical Nameenzalutamide
Dosage FormCapsules (oral; 40mg); Tablets (oral; 40mg, 80mg)
Drug ClassInhibitors
SystemMale reproductive
CompanyAstellas Pharma Inc.
Approval Year2012

Indication

  • For the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xtandi (enzalutamide) Prescribing Information2012Astellas Pharma US Inc., Northbrook, IL
Document TitleYearSource
Final clinical guidance report: enzalutamide (xtandi).2020CADTH
Final economic guidance report: enzalutamide (xtandi).2020CADTH
Enzalutamide for hormone-relapsed non-metastatic prostate cancer.2019NICE
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.2016NICE
Document TitleYearSource
Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis.2020International Journal of Clinical Oncology
Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. 2020European Urology
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. 2020Prostate Cancer and Prostatic Diseases
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.2020Clinical Genitourinary Cancer
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. 2020Journal of Oncology Pharmacy Practice
Systemic management for non-metastatic castration-resistant prostate cancer. 2020American Journal of Clinical Oncology
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. 2020Prostate Cancer and Prostatic Diseases
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis.2020Journal of Pharmacy and Pharmaceutical Sciences
Comparative efficacy of combined radiotherapy, systemic therapy, and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A network meta-analysis and systematic review.2020Frontiers in Oncology
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer.2019Medicine
Third-line treatment and 177Lu-PSMA radio ligand therapy of metastatic castration-resistant prostate cancer: a systematic review.2018European Journal of Nuclear Medicine and Molecular Imaging
Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer.2018Value in Health
Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration‑resistant prostate cancer: a systematic review.2017Asian Journal of Andrology
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. 2017Current Medical Research and Opinion
First‐line non‐cytotoxic therapy in chemotherapy‐naive patients with metastatic castration‐resistant prostate cancer: a systematic review of 10 randomised clinical trials. 2017BJU International
Document TitleYearSource
EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. 2021European Association of Urology
Prostate cancer, version 2.2019.2019Journal of the National Comprehensive Cancer Network